BRAF and MEK inhibitors displayed high ORR, yet only lower than half of patients with BRAFV600-mutated melanoma could obtain long-term benefits form BRAF inhibitors.609 The ORR of ICBs is relatively lower than targeted therapies, although ICBs provide durable responses.610,611 Given that complementary clinical profiles led by targeted therapies and ICBs, the proposal that combinatorial regimen of these two therapies might provide durable response and elevated ORR, as well as lower toxicity are of great interest. This evidence concerns the gene BRAF and melanoma.